

ACE in Ischemic Heart Disease

Bibliography of One Hundred Key Papers

-
- Aberg G, Ferrer P.** *Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol.* 1990;15:S65-S72.
-
- ACE-inhibitor Myocardial Infarction Collaborative Group.** *Indications for ACE-inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation.* 1998;97:2202-2212.
-
- Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TIA, Jensen G, Tybjaerg-Hansen A.** *ACE gene polymorphism: ischemic heart disease and longevity in 10 150 individuals. A case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation.* 1997;95:2358-2367.
-
- Alderman MH, Madhavan SH, Ooi WL, et al.** *Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med.* 1991;324:1098-1104.
-
- Ambrosioni E, Borghi C, Magnani B, for the Survival of of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.** *The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after acute myocardial infarction. N Engl J Med.* 1995;332:80-85.
-
- Bell L, Madri JA.** *Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol.* 1990;137:7-12.
-
- Brown NJ, Vaughan DE.** *Angiotensin-converting enzyme inhibitors. Circulation.* 1998;97:1411-1420.
-
- Brunner HR, Laragh JH, Baer L, et al.** *Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med.* 1972;286:441-449.
-
- Cambien F, Poirier O, Lecerf L, et al.** *Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature.* 1992;359:641-644.
-
- Chaturvedi N, Sjolie AK, Stephenson JM, et al.** *Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet.* 1998;351:28-31.
-
- Chobanian AV, Haudenschild CC, Nickerson C, Drago R.** *Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension.* 1990;15:327-331.
-
- Cleland JGF, Henderson E, McLenachan JM, Findlay IN, Dargie HJ.** *Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol.* 1991;17:733-739.
-

Bibliography of One Hundred Key Papers

- Clozel M, Kuhn H, Hefti F, Baumgartner HR.** *Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition.* **Hypertension.** 1997;20:1767-1771.
-
- Collins R, Peto R, MacMahon S, et al.** *Blood pressure, stroke and coronary heart disease, II: effect of short-term reductions in blood pressure: an overview of randomized drug trials in an epidemiological context.* **Lancet.** 1990;335:827-838.
-
- Daemen MJAP, Lombardi DM, Bosman FT, Schwatz SM.** *Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.* **Circ Res.** 1991;68:450-456.
-
- Daly P, Mettauer P, Rouleau JL, Cousineau D, Burgess JH.** *Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect.* **Circulation.** 1985;71:317-325.
-
- Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ.** *Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease.* **Circulation.** 1996;94:2756-2767.
-
- Dzau VJ.** *Cardiac renin-angiotensin system: molecular and functional aspects.* **Am J Med.** 1988;84(suppl 3A):22-27.
-
- Dzau VJ.** *Renin and myocardial infarction in hypertension.* **N Engl J Med.** 1991;324:1128-1130.
-
- Dzau VJ.** *Angiotensin converting enzyme inhibitors and the cardiovascular system.* **J Hypertens.** 1992;10(suppl):S3-S10.
-
- Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW.** *The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.* **N Engl J Med.** 1998;338:645-652.
-
- Faxon DP, Creager MA, Halperin JL, Sussman HA, Gavras H, Ryan TJ.** *The effect of angiotensin converting enzyme inhibition on coronary coronary blood flow and hemodynamics in patients without coronary artery disease.* **Int J Cardiol.** 1982;2:251-262.
-
- Feener EP, Northup JM, Aiello LP, King GL.** *Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells.* **J Clin Invest.** 1995;95:1353-1362.
-
- Ferrario CM, Gildenberg PL, McCubbin JW.** *Cardiovascular actions of angiotensin mediated by the central nervous system.* **Circ Res.** 1972;30:257-262.
-
- Flather M, Kober L, Pfeffer MA, et al.** *Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction (SAVE, AIRE and TRACE studies).* **Circulation.** 1997;96(suppl I):1-706.
-



-
- Francis G, Benedict C, Johnstone DE, et al.** *Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD).* **Circulation.** 1990;82:1724-1729.
-
- Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials.** *Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.* **JAMA.** 1995;18:1450-1456.
-
- Gavras H, Brown JJ, Lever AF, Macadam RF, Robertson JIS.** *Acute renal failure, tubular necrosis and myocardial infarction induced into the rabbit by intravenous angiotensin-II.* **Lancet.** 1971;122:1382-1388.
-
- Gibbons GH.** *Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide.* **Clin Cardiol.** 1997;29(suppl II):II18-II25.
-
- Gibbons GH, Dzau VJ.** *The emerging concept of vascular remodeling.* **N Engl J Med.** 1994;330:1431-1433.
-
- GLANT Study Group.** *A 12-month comparison of ACE inhibitor and calcium antagonist therapy in mild to moderate essential hypertension.* **Hypertens Res.** 1995;18:235-244.
-
- Goldsmith SR, Haskins GJ, Miller E.** *Angiotensin II and sympathetic activity in patients with congestive heart failure.* **J Am Coll Cardiol.** 1993;21:1107-1113.
-
- Griendling KK, Murphy TJ, Alexander RW.** *Molecular biology of the renin-angiotensin system.* **Circulation.** 1993;87:1816-1828.
-
- Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.** *GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.* **Lancet.** 1995;345:669-685.
-
- Hansson L, Lindholm LH, Niskanen L, et al, for the Captopril Prevention Project (CAPPP) Study Group.** *Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP).* **Lancet.** 1999;353:611-616.
-
- Harrison DG.** *Endothelial function and oxidant stress.* **Clin Cardiol.** 1997;20(suppl II):II11-II17.
-
- Hernandez-Presa M, Bustos C, Ortego M, et al.** *Angiotensin-converting enzyme inhibition prevents arterial nuclear factor- κ B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis.* **Circulation.** 1997;95:1532-1541.
-
- Hornig B, Kohler C, Drexler H.** *Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.* **Circulation.** 1997;95:1115-1118.
-

Bibliography of One Hundred Key Papers

- ISIS-4 Collaborative Group.** *ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction.* **Lancet.** 1995;345:669-685.
-
- Katz AM.** *Angiotensin II: hemodynamic regulator or growth factor?* **J Mol Cell Cardiol.** 1990;22:739-747.
-
- Klein WW, Khurmi NS, Eber B, et al.** *Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina.* **J Am Coll Cardiol.** 1990;16:948-956.
-
- Kober L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group.** *A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.* **N Engl J Med.** 1995; 333:1670-1676.
-
- Lees RS, Pitt B, Chan RC, et al, for the QUIET Investigators.** *Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) trial.* **Am J Cardiol.** 1996;78:1011-1016.
-
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group.** *The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.* **N Engl J Med.** 1993;329:1456-1462.
-
- Lindpainter K, Ganten D.** *The cardiac renin-angiotensin system: a synopsis of current experimental and clinical data.* **Acta Cardiol.** 1991;46:385-397.
-
- Lindpainter K, Pfeffer M.** *Molecular genetics crying wolf? The case of the angiotensin-converting enzyme gene and cardiovascular disease.* **J Am Coll Cardiol.** 1995;25:1632-1633.
-
- Lindpaintner K, Pfeffer MA, Kreutz R, et al.** *A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.* **N Engl J Med.** 1995;332:706-711.
-
- Linz W, Scholkens BA, Ganten D.** *Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.* **Clin Exp Hypertens.** 1989;11:1325-1350.
-
- Linz W, Wiemer G, Scholkens BA.** *Contribution of bradykinin to the cardiovascular effects of ramipril.* **J Cardiovasc Pharmacol.** 1993;22(suppl 9):S1-S8.
-
- Lonn E, Yusuf S, Doris CI, et al, for the SECURE Investigators.** *Study design and baseline characteristics of the Study to Evaluate Carotid Ultrasound Changes in patients treated with Ramipril and vitamin E: SECURE.* **Am J Cardiol.** 1996;78:914-919.
-
- Lonn EM, Yusuf S, Jha P, et al.** *Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.* **Circulation.** 1994;90:2056-2069.
-
- Ludwig M, Stumpe KO, Heagerty AM, et al.** *Vascular wall thickness in hypertension: the Perindopril Regression Vascular Thickening European community Trial (PROTECT).* **J Hypertens.** 1993;11(suppl 5):S316-S317.
-



-
- Magrini F, Shimizu M, Roberts N, Fouad FM, Tarazi RC, Zanchetti A** *Converting-enzyme inhibition and coronary blood flow.*
Circulation. 1987;75(suppl I):I168-I174.
-
- Mancini J, Henry GC, Macaya C, et al.** *Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study.*
Circulation. 1996;94:258-265.
-
- MARCATOR Investigators.** *The effect of high-dose angiotensin-converting enzyme inhibitor on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril.*
J Am Coll Cardiol. 1995;25:362-369.
-
- Maschio G, Alberti D, Janin G, et al.** *Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency.*
N Engl J Med. 1996;334:939-945.
-
- Meade TW, Cooper JA, Peart WS.** *Plasma renin activity and ischemic heart disease.*
N Engl J Med. 1993;329:616-619.
-
- Meade TW, Imeson JD, Gordon D, Peart WS.** *The epidemiology of plasma renin.*
Clin Sci. 1983;64:273-280.
-
- MERCATOR Study Group.** *Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?*
Circulation. 1992;86:100-110.
-
- Naftilan AJ, Pratt RE, Dzau VJ.** *Induction of platelet-derived growth-factor A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells.*
J Clin Invest. 1989;83:1419-1424.
-
- Naftilan AJ, Pratt RE, Eldridge CS, Lin HL, Dzau VJ.** *Angiotensin II induces c-fos expression in smooth muscle via transcriptional control.*
Hypertension. 1989;13:706-711.
-
- Nakashima Y, Fouad FM, Tarazi RC.** *Regression of left ventricular hypertrophy from systemic hypertension by enalapril.*
Am J Cardiol. 1984;53:1044-1049.
-
- Odenthal HJ, Thormann P, Wiechmann HW, et al.** *Behandlung der chronisch stabilen Angina pectoris durch Angiotensin-Converting-Enzym Hemmung. Eine randomisierte, placebokontrollierte, doppelblind-cross-over Studie [Treatment of chronic stable angina pectoris by angiotensin-converting enzyme inhibition. A randomized, placebo-controlled, double-blind, crossover study].*
Z Kardiol. 1991;80:392-396.
-
- Pfeffer MA, Braunwald E, Moye LA, et al.** *Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.*
N Engl J Med. 1992;327:669-677.
-
- Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E.** *Effect of captopril on progressive ventricular dilation after anterior myocardial infarction.*
N Engl J Med. 1988;319:80-86.
-

Bibliography of One Hundred Key Papers

- Pfeffer MA, Pfeffer JM, Steinberg C, Finn P.** *Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.*
Circulation. 1985;72:406-412.
-
- Pollane T, Lithell H, Berne C.** *A comparison of the effects of hydrochlorothiazide and captopril in glucose and lipid metabolism in patients with hypertension.*
N Engl J Med. 1989;321:868-873.
-
- Powell JS, Clozel JP, Muller RKM, et al.** *Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.*
Science. 1989;245:186-188.
-
- Powers ER, Bannerman KS, Stone J, et al.** *The effect of captopril on renal, coronary and systemic hemodynamics in patients with severe congestive heart failure.*
Am Heart J. 1982;104:1203-1210.
-
- Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE.** *Vascular injury induces angiotensinogen gene expression in the media and neointima.*
Circulation. 1993;87:283-290.
-
- Raynolds MV, Bristow MR, Bush EW, et al.** *Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy.*
Lancet. 1993;342:1073-1075.
-
- Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE.** *Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.*
Circulation. 1993;87:1969-1973.
-
- Rietbrock N, Thurmann P, Kirschen R, et al.** *Antiischämische Wirksamkeit von Enalapril bei Koronäre Herzkrankheit [Anti-ischemic efficacy of enalapril in coronary heart disease].*
Dtsch Med Wochenschr. 1988;113:300-302.
-
- Rolland PH, Carpiot P, Friggi A, et al.** *Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure and wall rheology in the hindquarters of atherosclerotic mini-pigs.*
Am J Cardiol. 1993;71:22E-27E.
-
- Rosendorff C.** *The renin-angiotensin system and vascular hypertrophy.*
J Am Coll Cardiol. 1996;28:803-812.
-
- Rutherford JD, Pfeffer MA, Moye LA, et al, on behalf of the SAVE Investigators.** *Effects of captopril on ischemic events after myocardial infarction. Results of the Survival And Ventricular Enlargement trial.*
Circulation. 1994;90:1731-1738.
-
- Samani N, Thompson JR, O'Toole L, Channer K, Woods KL.** *A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction.*
Circulation. 1996;94:708-712.
-
- Sharpe N, Murphy J, Smith H, Hannan S.** *Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.*
Lancet. 1988;1:255-259.
-



-
- Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G.** *Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.* **Lancet.** 1991;337:872-876.
-
- Singer DRJ, Missouris CG, Jeffery S.** *Angiotensin-converting enzyme gene polymorphism. What to do about all the confusion?* **Circulation.** 1996;94:236-239.
-
- Sogaard P, Gotzche CO, Ravkilde J, Thygesen K.** *Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction. .* **Circulation.** 1993;87:1093-1099.
-
- SOLVD Investigators.** *Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.* **N Engl J Med.** 1991;325:293-302.
-
- Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K.** *Suppressive effects of captopril on platelet aggregation in essential hypertension.* **J Cardiovasc Pharmacol.** 1984;6:840-843.
-
- Strozzi C, Cocco G, Portaluppi F, et al.** *Effects of captopril on the physical work capacity of normotensive patients with stable effort angina pectoris.* **Cardiology.** 1987;74:226-228.
-
- Swedberg K, Held P, Kjekshus J, et al, on behalf of the CONSENSUS II Study Group.** *Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the COoperative New Scandinavian ENalapril SURvival Study II (CONSENSUS II).* **N Engl J Med.** 1992;327:678-684.
-
- Swedberg K, Sharpe N.** *The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction.* **Eur Heart J.** 1996;17:1306-1311.
-
- Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo F.** *Outcome results of the fosinopril versus amlodipine cardiovascular events trial (FACET) in patients with hypertension and NIDDM.* **Diabetes Care.** 1998;21:597-603.
-
- The CONSENSUS Trial Study Group.** *Effects of enalapril on mortality in severe congestive heart failure.* **N Engl J Med.** 1987;316:1429-1435.
-
- The SOLVD Investigators.** *Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.* **N Engl J Med.** 1992;327:685-691.
-
- The SOLVD Investigators.** *Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.* **N Engl J Med.** 1992;327:685-691.
-
- The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.** *The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.* **Arch Intern Med.** 1997;157:2413-2446.
-

Bibliography of One Hundred Key Papers

- The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.** *Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.* **Lancet.** 1993;342:821-828.
-
- The PHYLLIS Project Group.** *Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolemic hypertensive subjects.* **J Hypertens.** 1993;11(suppl 5):S314-S315.
-
- Tiret L, Kee F, Poirier O, et al.** *Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction.* **Lancet.** 1993;341:991-992.
-
- UK Prospective Diabetes Study Group.** *Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.* **BMJ.** 1998;317:713-720.
-
- Van Gilst WH, Graeff PA, Scholtens E, deLangen CDJ, Wesseling H.** *Potential of isosorbide dinitrate-induced coronary dilation by captopril.* **J Cardiovasc Pharmacol.** 1987;9:254-255.
-
- Vaughan DE, Lazos SA, Tong K.** *Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells.* **J Clin Invest.** 1995;95:995-1001.
-
- Vaughan DE, Rouleau JL, Ridker PM, et al, on behalf of the HEART Study Investigators.** *Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction.* **Circulation.** 1997;96:442-447.
-
- Weber KT, Brilla CG.** *Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system.* **Circulation.** 1991;83:1849-1865.
-
- Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA.** *Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.* **J Am Coll Cardiol.** 1994;24:67-73.
-
- Yamabe T, Mazu M, Yamamoto H, et al.** *Effect of cilazapril on vascular restenosis after percutaneous transluminal coronary angioplasty.* **Cor Art Dis.** 1995;8:573-579.
-
- Yusuf S, Lonn E.** *Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials.* **Eur Heart J.** 1998;19(suppl J):J36-J44.
-
- Yusuf S, Pepine CJ, Garces C, et al.** *Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.* **Lancet.** 1992;340:1173-1178.
-